Mark Zitter, MBA, Discusses Implications of Co-Pay Offset Programs for Managed Care

In this video, Mark Zitter, MBA, talks about the implications of Co-Pay Offset Programs for managed care. "Co-pay programs affect managed care very differently depending on the nature of the program," says Zitter. "These programs are tremendously varied."

Related Videos

Related Content

Advertisement

June 26th 2025

Improve Antiobesity Medication Adherence to Improve Results: Hamlet Gasoyan, PhD

Hayden E. Klein Hamlet Gasoyan, PhD

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

June 20th 2025

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

Julia Bonavitacola Colleen Kelley, MD, MPH

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 19th 2025

Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

Julia Bonavitacola Onyema Ogbuagu, MBBCh, FACP, FIDSA

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

Related Content

Advertisement

June 26th 2025

Improve Antiobesity Medication Adherence to Improve Results: Hamlet Gasoyan, PhD

Hayden E. Klein Hamlet Gasoyan, PhD

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

June 20th 2025

Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

Julia Bonavitacola Colleen Kelley, MD, MPH

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

June 19th 2025

Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

Julia Bonavitacola Onyema Ogbuagu, MBBCh, FACP, FIDSA

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

Laura Joszt, MA Hayden E. Klein Mansi Shah, MD

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.